Yingjiang Zhou
Overview
Explore the profile of Yingjiang Zhou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
1847
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Coyne E, Nie Y, Lee D, Pandovski S, Yang T, Zhou H, et al.
Hepatol Commun
. 2025 Feb;
9(2).
PMID: 39927988
Background: Metabolic dysfunction-associated steatotic liver disease is a prevalent disease that affects nearly one-third of the global population. Recent genome-wide association studies revealed that a common missense variant in the...
2.
Mathiowetz A, Meymand E, Deol K, Parlakgul G, Lange M, Pang S, et al.
bioRxiv
. 2024 Jun;
PMID: 38895340
Imbalances in lipid storage and secretion lead to the accumulation of hepatocyte lipid droplets (LDs) (i.e., hepatic steatosis). Our understanding of the mechanisms that govern the channeling of hepatocyte neutral...
3.
Yang X, Zhou Y, Gao Z
Neural Netw
. 2022 Dec;
158:132-141.
PMID: 36455428
We study the robust stabilization problem of a class of nonlinear systems with asymmetric saturating actuators and mismatched disturbances. Initially, we convert such a robust stabilization problem into a nonlinear-constrained...
4.
Jensen-Cody S, Coyne E, Ding X, Sebin A, Vogel J, Goldstein J, et al.
Am J Physiol Endocrinol Metab
. 2022 Apr;
322(6):E517-E527.
PMID: 35403438
Insulin resistance is a major public health burden that often results in other comorbidities including type 2 diabetes, nonalcoholic fatty liver disease (NAFLD), and cardiovascular disease. An insulin sensitizer has...
5.
Satapati S, Downes D, Metzger D, Shankaran H, Talukdar S, Zhou Y, et al.
SLAS Discov
. 2022 Jan;
27(1):20-28.
PMID: 35058172
Screening campaigns, especially those aimed at modulating enzyme activity, often rely on measuring substrate→product conversions. Unfortunately, the presence of endogenous substrates and/or products can limit one's ability to measure conversions....
6.
Ding X, Iyer R, Novotny C, Metzger D, Zhou H, Smith G, et al.
Sci Rep
. 2020 Feb;
10(1):3417.
PMID: 32099031
Insulin resistance increases patients' risk of developing type 2 diabetes (T2D), non-alcoholic steatohepatitis (NASH) and a host of other comorbidities including cardiovascular disease and cancer. At the molecular level, insulin...
7.
Guo W, Ong Y, Zhou Y, Hervas J, Song A, Wei H
IEEE Trans Cybern
. 2018 Jul;
49(8):3088-3098.
PMID: 29994240
The multilayer perceptrons (MLPs) are widely used in many fields, however, singularities in the parameter space may seriously influence the learning dynamics of MLPs and cause strange learning behaviors. Given...
8.
Weng Y, Ishino T, Sievers A, Talukdar S, Chabot J, Tam A, et al.
Sci Rep
. 2018 Mar;
8(1):4241.
PMID: 29523796
Pharmacological administration of FGF21 analogues has shown robust body weight reduction and lipid profile improvement in both dysmetabolic animal models and metabolic disease patients. Here we report the design, optimization,...
9.
Thompson W, Zhou Y, Talukdar S, Musante C
J Pharmacokinet Pharmacodyn
. 2016 Jul;
43(4):411-25.
PMID: 27405817
PF-05231023, a long-acting FGF21 analogue, is a promising potential pharmacotherapy for the treatment of obesity and associated comorbidities. Previous studies have shown the potential of FGF21 and FGF21-like compounds to...
10.
Herrema H, Zhou Y, Zhang D, Lee J, Hernandez M, Shulman G, et al.
J Biol Chem
. 2016 Jun;
291(33):17394-404.
PMID: 27325692
Endoplasmic reticulum (ER) stress has been shown to contribute to various metabolic diseases, including non-alcoholic fatty liver disease and type 2 diabetes. Reduction of ER stress by treatment with chemical...